Article: The Medicines Company Announces Publication of First Ever Randomized Clinical Trial Assessing Replacement for Heparin in CABG Surgery.

Business Editors/Health/Medical Writers

PARSIPPANY, N.J.--(BUSINESS WIRE)--March 4, 2004

The Medicines Company (Nasdaq: MDCO):

-- Annals of Thoracic Surgery reports bivalirudin (Angiomax(R))

anticoagulation feasible in off-pump coronary artery bypass

graft surgery

-- Patients in bivalirudin group had better graft flow at 90-days

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!